NewAmsterdam Pharma (NASDAQ:NAMSW – Get Free Report) was the target of a large growth in short interest in June. As of June 15th, there was short interest totalling 12,100 shares, a growth of 21.0% from the May 31st total of 10,000 shares. Based on an average daily volume of 5,500 shares, the days-to-cover ratio is currently 2.2 days.
NewAmsterdam Pharma Stock Performance
NAMSW stock traded up $1.39 during midday trading on Tuesday, reaching $10.40. 8,765 shares of the company’s stock traded hands, compared to its average volume of 12,671. The firm’s fifty day moving average price is $9.22 and its 200-day moving average price is $8.69. NewAmsterdam Pharma has a 52 week low of $0.99 and a 52 week high of $14.67.
Institutional Trading of NewAmsterdam Pharma
An institutional investor recently raised its position in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC increased its stake in NewAmsterdam Pharma (NASDAQ:NAMSW – Free Report) by 47.9% during the first quarter, according to its most recent filing with the SEC. The fund owned 202,599 shares of the company’s stock after buying an additional 65,599 shares during the quarter. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $2,237,000 at the end of the most recent quarter.
NewAmsterdam Pharma Company Profile
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Further Reading
- Five stocks we like better than NewAmsterdam Pharma
- Investing In Preferred Stock vs. Common Stock
- RXO Shares Surge Following New Acquisition Deal
- Why Invest in 5G? How to Invest in 5G Stocks
- 3 Stock Dips Insiders Are Buying: Vestis, Shenandoah, Treace
- Energy and Oil Stocks Explained
- Biotech Stock Breakout: IBB Eyes Resistance with Amgen and Vertex
Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.